ANDROFERT, Andrology and Human Reproduction Clinic, Campinas, Brazil.; Department of Surgery (Division of Urology), University of Campinas (UNICAMP), Campinas, Brazil.; Faculty of Health, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark..
Fertility Clinic at Skive Regional Hospital, Faculty of Health, Aarhus University, Aarhus, Denmark.
Reprod Biomed Online. 2024 Apr;48(4):103647. doi: 10.1016/j.rbmo.2023.103647. Epub 2023 Oct 29.
Can a novel classification system of the infertile male - 'APHRODITE' (Addressing male Patients with Hypogonadism and/or infeRtility Owing to altereD, Idiopathic TEsticular function) - stratify different subgroups of male infertility to help scientists to design clinical trials on the hormonal treatment of male infertility, and clinicians to counsel and treat the endocrinological imbalances in men and, ultimately, increase the chances of natural and assisted conception?
A collaboration between andrologists, reproductive urologists and gynaecologists, with specialization in reproductive medicine and expertise in male infertility, led to the development of the APHRODITE criteria through an iterative consensus process based on clinical patient descriptions and the results of routine laboratory tests, including semen analysis and hormonal testing.
Five patient groups were delineated according to the APHRODITE criteria; (1) Hypogonadotrophic hypogonadism (acquired and congenital); (2) Idiopathic male infertility with lowered semen analysis parameters, normal serum FSH and normal serum total testosterone concentrations; (3) A hypogonadal state with lowered semen analysis parameters, normal FSH and reduced total testosterone concentrations; (4) Lowered semen analysis parameters, elevated FSH concentrations and reduced or normal total testosterone concentrations; and (5) Unexplained male infertility in the context of unexplained couple infertility.
The APHRODITE criteria offer a novel and standardized patient stratification system for male infertility independent of aetiology and/or altered spermatogenesis, facilitating communication among clinicians, researchers and patients to improve reproductive outcomes following hormonal therapy. APHRODITE is proposed as a basis for future trials of the hormonal treatment of male infertility.
一种新的不育男性分类系统——“APHRODITE”(针对因睾丸功能障碍和/或特发性改变而导致性腺功能减退和/或不育的男性患者)——是否可以将男性不育的不同亚组分层,以帮助科学家设计男性不育的激素治疗临床试验,以及为临床医生提供咨询和治疗男性内分泌失衡,并最终增加自然和辅助受孕的机会?
通过一个迭代共识过程,由男科医生、生殖泌尿科医生和妇科医生合作,他们专门从事生殖医学,并在男性不育方面具有专业知识,从而制定了 APHRODITE 标准。该过程基于临床患者描述和常规实验室测试结果(包括精液分析和激素测试)。
根据 APHRODITE 标准,确定了五个患者组;(1)促性腺激素缺乏性性腺功能减退症(获得性和先天性);(2)特发性男性不育症,精液分析参数降低,血清 FSH 和总睾酮浓度正常;(3)低性腺状态,精液分析参数降低,FSH 正常,总睾酮浓度降低;(4)精液分析参数降低,FSH 浓度升高,总睾酮浓度降低或正常;(5)在不明原因夫妇不育的情况下出现不明原因的男性不育。
APHRODITE 标准为男性不育提供了一种新的、标准化的患者分层系统,与病因和/或改变的精子发生无关,促进了临床医生、研究人员和患者之间的沟通,以改善激素治疗后的生殖结果。APHRODITE 被提议作为未来男性不育激素治疗试验的基础。